Skip to main content

Advertisement

SpringerLink
Log in

The Rezūm System: Minimally Invasive Treatment for BPH Using Water Vapor (Steam): Why Consider It?

  • BPH-Related Voiding Dysfunction (R Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

The Rezūm System™ is based on phase-change convective heat transfer with water vapor (steam) to ablate tissue. This is distinctly different than conductive heat transfer used by earlier devices such as radiofrequency or microwave systems. A summary of the early work is presented as well as a discussion of the important principles that make phase-change convective heating particularly useful in the prostate. Preliminary work suggests clinical promise for treating men with BPH and has led to a large scale trial to assess safety and efficacy of the procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968;49:347–57.

    CAS  PubMed  Google Scholar 

  2. Dixon CM, Cedano ER, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm® system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:1–6. This reference provides compelling evidence that vapor can effectively ablate BPH.

    Google Scholar 

  3. Mynderse LA, Hanson D, Robb R, Pacik D, Vit V, Varga G, et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3D renderings. Submitted for publication February 2015. This reference provides serial MRI evidence that vapor can effectively ablate BPH.

  4. Dixon C, Rijo Cedano E, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Submitted for publication February 2015. This reference presents the early, one year clinical data in men with BPH.

  5. Abraham JP, Sparrow EM. A thermal-ablation bioheat model including liquid-to-vapor phase change, pressure- and necrosis-dependent perfusion, and moisture-dependent properties. Int J Heat Mass Transf. 2007;50:2537–44.

    Article  Google Scholar 

  6. Coad JE, Bischof JC. Histologic differences between hyperthermic and cryothermic therapies. Thermal treatment of tissue energy delivery and assessment II. Soc Photo-Opt Instrum Eng. 2003;4954:27–36.

    Google Scholar 

  7. Coad JE. Thermal fixation: a central outcome of hyperthermic therapies. Proc SPIE. 2005;5698:15–22.

    Article  Google Scholar 

  8. Dixon CM et al. MP04-08 development of convective water vapor therapy (steam) for focal therapy of prostate cancer. Human extirpated prostate and cadaveric studies. J Endourol. 2014;28(Supplement 1):9.

    Google Scholar 

  9. Dixon CM et al. MP04-09 development of convective water vapor therapy (steam) for focal therapy of prostate cancer. In vivo treatment and immediate radical prostatectomy. J Endourol. 2014;28(Supplement 1):9.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Christopher Dixon MD I am a paid for time and expenses.

Michael Hoey is the founder and Chief Technology Officer of NxThera Inc.

Thayne Larson MD is a paid consultant but I do not know his financial arrangement with NxThera.

All of the studies referenced have been performed with Ethics Committee Approvals in the respective countries. Only the physician authors have particicpated in direct patient care with the local treating physicians.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, Lenox Hill Hospital, 4 East Building, 100 E 77th St, New York, NY, 10065, USA

    Christopher Dixon

  2. Institute of Medical Research, Phoenix, AZ, USA

    Thayne Larson

  3. NxThera Inc., Maple Grove, MN, USA

    Michael Hoey

Authors
  1. Christopher Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thayne Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Hoey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Dixon.

Additional information

This article is part of the Topical Collection on BPH-Related Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dixon, C., Larson, T. & Hoey, M. The Rezūm System: Minimally Invasive Treatment for BPH Using Water Vapor (Steam): Why Consider It?. Curr Bladder Dysfunct Rep 10, 156–159 (2015). https://doi.org/10.1007/s11884-015-0300-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-015-0300-0

Keywords

Search

Navigation